GAMMA Investing LLC Boosts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

GAMMA Investing LLC grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 67.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 867 shares of the biopharmaceutical company’s stock after purchasing an additional 350 shares during the period. GAMMA Investing LLC’s holdings in Halozyme Therapeutics were worth $50,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Rise Advisors LLC bought a new stake in Halozyme Therapeutics during the first quarter worth about $25,000. International Assets Investment Management LLC bought a new stake in Halozyme Therapeutics in the 2nd quarter worth approximately $33,000. Whittier Trust Co. bought a new stake in Halozyme Therapeutics in the 1st quarter worth approximately $27,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in Halozyme Therapeutics in the second quarter worth approximately $49,000. Finally, Fidelis Capital Partners LLC bought a new position in Halozyme Therapeutics during the first quarter valued at approximately $52,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on HALO shares. Morgan Stanley boosted their price objective on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Benchmark reissued a “buy” rating and issued a $60.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, October 4th. The Goldman Sachs Group lifted their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a report on Monday, July 22nd. Finally, TD Cowen increased their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $60.44.

Halozyme Therapeutics Stock Down 0.7 %

NASDAQ HALO opened at $53.46 on Thursday. Halozyme Therapeutics, Inc. has a 1 year low of $32.83 and a 1 year high of $65.53. The stock has a market capitalization of $6.80 billion, a PE ratio of 22.09, a PEG ratio of 0.49 and a beta of 1.27. The company has a debt-to-equity ratio of 5.19, a current ratio of 7.41 and a quick ratio of 6.21. The business’s 50-day moving average is $58.80 and its 200 day moving average is $51.04.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. The firm had revenue of $231.40 million for the quarter, compared to analyst estimates of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company earned $0.68 EPS. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In other news, CFO Nicole Labrosse sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $53.93, for a total value of $269,650.00. Following the completion of the sale, the chief financial officer now directly owns 15,480 shares of the company’s stock, valued at approximately $834,836.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total transaction of $592,000.00. Following the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at $40,063,244.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Nicole Labrosse sold 5,000 shares of the stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total value of $269,650.00. Following the completion of the transaction, the chief financial officer now owns 15,480 shares of the company’s stock, valued at approximately $834,836.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 104,881 shares of company stock worth $5,990,684 over the last quarter. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.